Loading...
Loading...
INKT| Name | Value |
|---|---|
| Revenues | 11.7B |
| Cost of Revenue | 5.9B |
| Gross Profit | 5.9B |
| Operating Expense | 0.0B |
| Operating I/L | -0.0B |
| Other Income/Expense | 0.0B |
| Interest Income | 0.0B |
| Pretax | -0.0B |
| Income Tax Expense | -0.2B |
| Net Income/Loss | 0.2B |
MiNK Therapeutics, Inc. is a clinical stage biopharmaceutical company specializing in the development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Their lead product candidate, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy for various myeloma diseases currently in Phase 1 clinical trials. The company's revenue model is centered around the research, development, and eventual commercialization of these innovative cell therapies for the treatment of diseases.
